Clinical Report: Gastrointestinal Adverse Effects Linked to CDK4/6 Inhibitors

Overview

This study assessed gastrointestinal adverse events (AEs) associated with CDK4/6 inhibitors in breast cancer patients using real-world data. Significant findings include heterogeneous reporting patterns and the identification of unlabeled pharmacovigilance signals.

Background

CDK4/6 inhibitors are critical in treating hormone receptor-positive breast cancer, yet their gastrointestinal safety profile is not fully characterized. Understanding the adverse effects is important as they can lead to treatment interruptions.

Data Highlights

Key Findings

• 63,722 reports associated with CDK4/6 inhibitors; 18,589 involved GI AEs.
• Palbociclib had the highest proportion of GI AE reports, particularly for oropharyngeal and upper GI events.
• Ribociclib showed the highest proportion of serious GI reports (82.38%), with 14.25% fatal outcomes.
• Abemaciclib's strongest signal was for diarrhea, with gastrointestinal disorders as the most frequently reported class.
• Over 80% of positive GI signals were not included in current prescribing information.
• Median onset times varied significantly: 15 days for abemaciclib, 27 days for ribociclib, and 49 days for palbociclib (p < 0.001).

Clinical Implications

Healthcare providers should monitor for gastrointestinal symptoms in patients receiving ribociclib, given its high rate of serious AEs.

Conclusion

This study revealed heterogeneous disproportionate reporting patterns for GI AEs among CDK4/6 inhibitors and identified unlabeled pharmacovigilance signals.

Related Resources & Content

1. The ASCO Post, 2017 -- Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting
2. Frontiers in Immunology, 2026 -- CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers
3. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer - ScienceDirect
4. The ASCO Post — Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting
5. The ASCO Post — CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future
6. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer - ScienceDirect
7. Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2 | JCO Oncology Advances
8. Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system